ClinicalTrials.gg
CompletedNCT00862784Updated Jun 17, 2014Results posted

A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer

A Phase 2 interventional study of IMC-1121B (ramucirumab) and Oxaliplatin in Colorectal Carcinoma, sponsored by Eli Lilly and Company. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-17.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Colorectal Neoplasms by Eli Lilly and Company — 4 open to participants now, 7 under way, none of them phase 3. Colorectal Neoplasms · Eli Lilly and Company.

Enrollment
24th of 34
48 · median 103
Started
2009
with 1 other
Phase 2
16 of 37
1 open now
Registered
18th of 37
by date

Among the 37 studies in Colorectal Neoplasms by Eli Lilly and Company, this one is the 24th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2009, is one of 16 in phase 2, and was the 18th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

4 of the 37 studies in Colorectal Neoplasms by Eli Lilly and Company are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Colorectal Neoplasms by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to test how long participants with colorectal cancer live without progressive disease when being treated with IMC-1121B (ramucirumab) and the modified FOLFOX-6 chemotherapy.

Read the detailed description

The purpose of this study is to evaluate the progression-free survival (PFS) in participants with metastatic colorectal cancer when treated with the monoclonal antibody IMC-1121B (ramucirumab) in combination with the modified FOLFOX-6 [folinic acid (FA) + fluorouracil (5-FU) + oxaliplatin, mFOLFOX-6] chemotherapy regimen as first-line therapy.

03

Conditions studied

  • Colorectal Carcinoma

Keywords

  • Colorectal carcinoma
  • CRC
  • Colon Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant must have confirmed adenocarcinoma of the colon or rectum that is locally-advanced or and unresectable
  • The participant has at least one unidimensionally-measurable target lesion [≥ 2 centimeters (cm) with conventional techniques or ≥ 1 cm with spiral computed tomography (CT) scan or magnetic resonance imaging (MRI), as defined by (RECIST)]; target lesion(s) must not lie within an irradiated area. Participants with locally advanced rectal carcinoma who have undergone previous radiation must have documented evidence of disease progression in the pelvis in order to participate
  • The participant is age ≥ 18 years
  • The participant has a of ≥ 6 months
  • The participant has an Performance Status (ECOG PS) 0-1 at study entry
  • The participant has adequate hematologic function, as evidenced by an (ANC) ≥ 1500/microliter (μL), ≥ 10 grams/deciliter (g/dL), and ≥ 100,000/μL
  • The participant has adequate hepatic function as defined by: total ≤ 1.5 x (ULN), (AST) and alanine transaminase (ALT) ≤ 3.0 x ULN (or 5.0 x ULN in the case of liver metastases), and serum albumin ≥ lower limit of normal (LLN) institutional range or (if \< LLN) within 10% of the LLN
  • The participant has adequate renal function as defined by a serum creatinine ≤ 1.5 x ULN, or (measured via 24-hour urine collection) ≥ 60 milliliters/minute (mL/min)
  • The participant's urinary protein ≤ 1+ on dipstick or routine urinalysis [(UA); if urine dipstick or routine analysis is ≥ 2+, a 24-hour urine for protein must demonstrate \< 1000 milligrams (mg) of protein in 24 hours to allow participation in the study]
  • The participant must have adequate coagulation function as defined by (INR) ≤ 1.5 and a partial thromboplastin time (PTT) ≤ 5 seconds above the ULN. Participants on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight (LMW) heparin and if on warfarin, must have an INR between 2 and 3 and no active bleeding or pathological condition present that carries a high risk of bleeding (for example, tumor involving major vessels or known varices)
  • The participant has resolution to Grade ≤ 1 by the National Cancer Institute , Version 3 (NCI-CTCAE v 3.0) of all toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy with the exception of peripheral neuropathy which must have resolved to Grade 0
  • The participant agrees to use adequate during the study period and for 8 weeks after the last dose of study treatment
  • The participant has provided signed

Exclusion criteria

Exclusion Criteria:

  • The participant has received prior systemic chemotherapy for locally-advanced unresectable or colorectal cancer (CRC). Prior chemotherapy is allowed if disease progression has been documented > 6 months after the end of the last cycle of adjuvant chemotherapy or > 12 months after the end of the last cycle of adjuvant oxaliplatin-containing regimens
  • The participant has documented and/or symptomatic brain or
  • The participant has participated in clinical studies of non-approved experimental agents or procedures within 12 weeks of study entry
  • The participant has received previous therapy with monoclonal antibodies
  • The participant has received previous therapy with any agent that targets vascular endothelial growth factor (VEGF) or VEGF receptor-2 (VEGFR-2) (including multi-targeted tyrosine kinase inhibitors)
  • The participant has an ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorders in the opinion of the investigator
  • The participant is on chronic non-topical treatment for > 6 months at doses > 10 mg/day of prednisolone or equivalent before study entry, which in the opinion of the investigator could compromise the participant or the study
  • The participant has a known dihydropyrimidine dehydrogenase (DPD) deficiency
  • The participant has a known allergy to any of the treatment components
  • The participant has an acute or subacute intestinal obstruction
  • The participant has uncontrolled or poorly controlled hypertension on a standard regimen of anti-hypertensive therapy
  • The participant has a concurrent active other than adequately treated nonmelanomatous skin cancer, other noninvasive carcinoma, or in situ neoplasm. A participant with previous history of malignancy is eligible, provided that he/she has been disease free for > 3 years
  • The participant, if female, is pregnant
  • Has had prior autologous or allogeneic organ or tissue transplantation
  • Has interstitial pneumonia or interstitial fibrosis of the lung, which in the opinion of the investigator could compromise the participant or the study
  • Has pleural effusion or ascites that causes > Grade 1 dyspnea
  • Has psychological, familial, sociological, or geographical conditions which do not permit adequate study follow-up, compliance with the protocol, or signature of
  • Has undergone major surgery within 28 days prior to the first dose of study medication, or subcutaneous venous access device placement within 7 days prior to the first dose of study medication
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    IMC-1121B (ramucirumab) + mFOLFOX-6

    This regimen will be repeated every 2 weeks until disease progression, unacceptable toxicity, or withdrawal.

    Biological: IMC-1121B (ramucirumab) · Drug: Oxaliplatin · Drug: Folinic acid · Drug: 5-FU

Interventions

  • 8 milligrams/kilogram (mg/kg) IMC-1121B (ramucirumab) infusions every 2 weeks

    Also known as: ramucirumab, LY3009806

  • 85 milligrams/square meter (mg/m²) intravenous infusion over 2 hours on Day 1

  • 400 mg/m² intravenous infusion over 2 hours on Day 1

  • Drug5-FU

    400 mg/m² intravenous bolus injection over 2-4 minutes, immediately following folinic acid infusion

  • Drug5-FU

    2400 mg/m² intravenous continuous infusion over 46 hours immediately following bolus 5-FU on Days 1 and 2

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined as the time from date of first dose to the first observation of progression of disease (PD) or death due to any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. PD is ≥20% increase in sum of longest diameter of target lesions and/or unequivocal progression of non-target lesion and/or new lesion. For participants who had no PD or death or had started new therapeutic anticancer treatment, PFS was censored at their last radiographic tumor assessment.

    Time frame: First dose to measured progressive disease or death due to any cause up to 28.1 months

Secondary outcomes

  1. Percentage of Participants With Complete Response or Partial Response [Objective Response Rate (ORR)]

    ORR is the percentage of participants with a confirmed complete response (CR) + partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. CR is disappearance of all target and non-target lesions; PR is a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesion. ORR is calculated as a total number of participants with CR or PR from the start of study treatment until disease progression or recurrence divided by the total number of participants treated, then multiplied by 100.

    Time frame: First dose to date of objective progressive disease up to 23.8 months

  2. Overall Survival (OS)

    OS was defined as the time from first dose to the date of death due to any cause. For participants who were alive or were lost to follow-up, OS was censored on the last date the participant was known to be alive.

    Time frame: First dose to death due to any cause up to 28.1 months

  3. Duration of Response

    The duration of response was defined as the time from first objective status assessment of complete response (CR) or partial response (PR) to the first time of progression or death as a result of any cause. CR or PR is classified by the investigators according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. CR is disappearance of all target and non-target lesions; PR is a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesion.

    Time frame: Time of response to time of measured progressive disease up to 22.2 months

  4. Number of Participants With IMC-1121B (Ramucirumab)-Related Adverse Events (AEs)

    Data presented are the number of participants who experienced AEs of any grade and AEs of Grade ≥3 based on National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 (NCI-CTCAE v 3.0), that were considered to be related to IMC-1121B (ramucirumab) by the investigators. A summary of serious AEs (SAEs) and all other non-serious AEs regardless of causality, is located in the Reported Adverse Events module.

    Time frame: First dose to 25.2 months

  5. Number of Participants With IMC-1121B (Ramucirumab)-Related Severe Adverse Events (SAEs)

    Data presented are the number of participants who experienced SAEs, adverse events (AEs) resulting in death and AEs leading to discontinuation of treatment, that were considered to be related to IMC-1121B (ramucirumab) by the investigators. A summary of SAEs and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: First dose to 25.2 months

  6. Maximum Concentration (Cmax) at Day 1 of Cycle 1

    Due to sparse pharmacokinetic schedule, Cmax was not calculated.

    Time frame: Baseline, 1, 168, and 336 hours post infusion on Day 1 (Cycle 1)

  7. Area Under the Concentration (AUC) at Day 1 of Cycle 1

    Due to sparse pharmacokinetic schedule, AUC was not calculated.

    Time frame: Baseline, 1, 168, and 336 hours post infusion on Day 1 (Cycle 1)

  8. Half-Life (t1/2) at Day 1 of Cycle 1

    Due to sparse pharmacokinetic schedule, t1/2 was not calculated.

    Time frame: Baseline, 1, 168, and 336 hours post infusion on Day 1 (Cycle 1)

  9. Clearance (CL) at Day 1 of Cycle 1

    Due to sparse pharmacokinetic schedule, CL was not calculated.

    Time frame: Baseline, 1, 168, and 336 hours post infusion on Day 1 (Cycle 1)

  10. Steady State Volume of Distribution (Vss) at Day 1 of Cycle 1

    Due to sparse pharmacokinetic schedule, Vss was not calculated.

    Time frame: Baseline, 1, 168, and 336 hours post infusion Day 1 (Cycle 1)

  11. Maximum Concentration (Cmax) at Day 1 of Cycles 5, 9, 13, 17, and 21

    Due to sparse pharmacokinetic schedule, Cmax was not calculated.

    Time frame: Baseline and 1 hour post infusion on Day 1 (Cycles 5, 9, 13, 17, and 21)

  12. Area Under the Concentration (AUC) at Day 1 of Cycles 5, 9, 13, 17, and 21

    Due to sparse pharmacokinetic schedule, AUC was not calculated.

    Time frame: Baseline and 1 hour post infusion on Day 1 (Cycles 5, 9, 13, 17, and 21)

  13. Half-Life (t1/2) at Day 1 of Cycles 5, 9, 13, 17, and 21

    Due to sparse pharmacokinetic schedule, t1/2 was not calculated.

    Time frame: Baseline and 1 hour post infusion on Day 1 (Cycles 5, 9, 13, 17, and 21)

  14. Clearance (CL) at Day 1 of Cycles 5, 9, 13, 17, and 21

    Due to sparse pharmacokinetic schedule, CL was not calculated.

    Time frame: Baseline and 1 hour post infusion on Day 1 (Cycles 5, 9, 13, 17, and 21)

  15. Steady State Volume of Distribution (Vss) at Day 1 of Cycles 5, 9, 13, 17, and 21

    Due to sparse pharmacokinetic schedule, Vss was not calculated.

    Time frame: Baseline and 1 hour post infusion on Day 1 (Cycles 5, 9, 13, 17, and 21)

  16. Serum Anti-IMC-1121B (Immunogenicity) at Day 1

    Data presented are the number of participants with treatment emergent anti-IMC-112B antibodies.

    Time frame: Day 1 (Cycles 1, 5, 9, and 30-day follow-up)

07

Results

Posted Jun 17, 2014

Participant flow

Participant flow — Overall Study
MilestoneIMC-1121B (Ramucirumab) + mFOLFOX-6
Started48
Received any amount of study drug48
Completed48
Not completed0

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS was defined as the time from date of first dose to the first observation of progression of disease (PD) or death due to any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. PD is ≥20% increase in sum of longest diameter of target lesions and/or unequivocal progression of non-target lesion and/or new lesion. For participants who had no PD or death or had started new therapeutic anticancer treatment, PFS was censored at their last radiographic tumor assessment.

Time frame:
First dose to measured progressive disease or death due to any cause up to 28.1 months
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsIMC-1121B (Ramucirumab) + mFOLFOX-6
Progression-Free Survival (PFS)11.5 (8.6 to 13.1)
SecondaryPercentage of Participants With Complete Response or Partial Response [Objective Response Rate (ORR)]

ORR is the percentage of participants with a confirmed complete response (CR) + partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. CR is disappearance of all target and non-target lesions; PR is a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesion. ORR is calculated as a total number of participants with CR or PR from the start of study treatment until disease progression or recurrence divided by the total number of participants treated, then multiplied by 100.

Time frame:
First dose to date of objective progressive disease up to 23.8 months
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response or Partial Response [Objective Response Rate (ORR)]
percentage of participantsIMC-1121B (Ramucirumab) + mFOLFOX-6
Percentage of Participants With Complete Response or Partial Response [Objective Response Rate (ORR)]58.3 (43.21 to 72.39)
SecondaryOverall Survival (OS)

OS was defined as the time from first dose to the date of death due to any cause. For participants who were alive or were lost to follow-up, OS was censored on the last date the participant was known to be alive.

Time frame:
First dose to death due to any cause up to 28.1 months
Reported as:
Median · months
Overall Survival (OS)
monthsIMC-1121B (Ramucirumab) + mFOLFOX-6
Overall Survival (OS)20.4 (18.5 to 25.1)
SecondaryDuration of Response

The duration of response was defined as the time from first objective status assessment of complete response (CR) or partial response (PR) to the first time of progression or death as a result of any cause. CR or PR is classified by the investigators according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. CR is disappearance of all target and non-target lesions; PR is a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesion.

Time frame:
Time of response to time of measured progressive disease up to 22.2 months
Reported as:
Median · months
Duration of Response
monthsIMC-1121B (Ramucirumab) + mFOLFOX-6
Duration of Response11.0 (6.9 to 12.6)
SecondaryNumber of Participants With IMC-1121B (Ramucirumab)-Related Adverse Events (AEs)

Data presented are the number of participants who experienced AEs of any grade and AEs of Grade ≥3 based on National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 (NCI-CTCAE v 3.0), that were considered to be related to IMC-1121B (ramucirumab) by the investigators. A summary of serious AEs (SAEs) and all other non-serious AEs regardless of causality, is located in the Reported Adverse Events module.

Time frame:
First dose to 25.2 months
Reported as:
Number · participants
Number of Participants With IMC-1121B (Ramucirumab)-Related Adverse Events (AEs)
participantsIMC-1121B (Ramucirumab) + mFOLFOX-6
Related AEs45
Related AEs of Grade ≥319
Related AE resulting in death2
Related AE leading to discontinuation11
SecondaryNumber of Participants With IMC-1121B (Ramucirumab)-Related Severe Adverse Events (SAEs)

Data presented are the number of participants who experienced SAEs, adverse events (AEs) resulting in death and AEs leading to discontinuation of treatment, that were considered to be related to IMC-1121B (ramucirumab) by the investigators. A summary of SAEs and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
First dose to 25.2 months
Reported as:
Number · participants
Number of Participants With IMC-1121B (Ramucirumab)-Related Severe Adverse Events (SAEs)
participantsIMC-1121B (Ramucirumab) + mFOLFOX-6
Number of Participants With IMC-1121B (Ramucirumab)-Related Severe Adverse Events (SAEs)10
SecondaryMaximum Concentration (Cmax) at Day 1 of Cycle 1

Due to sparse pharmacokinetic schedule, Cmax was not calculated.

Time frame:
Baseline, 1, 168, and 336 hours post infusion on Day 1 (Cycle 1)

No measurements were reported for this outcome.

SecondaryArea Under the Concentration (AUC) at Day 1 of Cycle 1

Due to sparse pharmacokinetic schedule, AUC was not calculated.

Time frame:
Baseline, 1, 168, and 336 hours post infusion on Day 1 (Cycle 1)

No measurements were reported for this outcome.

SecondaryHalf-Life (t1/2) at Day 1 of Cycle 1

Due to sparse pharmacokinetic schedule, t1/2 was not calculated.

Time frame:
Baseline, 1, 168, and 336 hours post infusion on Day 1 (Cycle 1)

No measurements were reported for this outcome.

SecondaryClearance (CL) at Day 1 of Cycle 1

Due to sparse pharmacokinetic schedule, CL was not calculated.

Time frame:
Baseline, 1, 168, and 336 hours post infusion on Day 1 (Cycle 1)

No measurements were reported for this outcome.

SecondarySteady State Volume of Distribution (Vss) at Day 1 of Cycle 1

Due to sparse pharmacokinetic schedule, Vss was not calculated.

Time frame:
Baseline, 1, 168, and 336 hours post infusion Day 1 (Cycle 1)

No measurements were reported for this outcome.

SecondaryMaximum Concentration (Cmax) at Day 1 of Cycles 5, 9, 13, 17, and 21

Due to sparse pharmacokinetic schedule, Cmax was not calculated.

Time frame:
Baseline and 1 hour post infusion on Day 1 (Cycles 5, 9, 13, 17, and 21)

No measurements were reported for this outcome.

SecondaryArea Under the Concentration (AUC) at Day 1 of Cycles 5, 9, 13, 17, and 21

Due to sparse pharmacokinetic schedule, AUC was not calculated.

Time frame:
Baseline and 1 hour post infusion on Day 1 (Cycles 5, 9, 13, 17, and 21)

No measurements were reported for this outcome.

SecondaryHalf-Life (t1/2) at Day 1 of Cycles 5, 9, 13, 17, and 21

Due to sparse pharmacokinetic schedule, t1/2 was not calculated.

Time frame:
Baseline and 1 hour post infusion on Day 1 (Cycles 5, 9, 13, 17, and 21)

No measurements were reported for this outcome.

SecondaryClearance (CL) at Day 1 of Cycles 5, 9, 13, 17, and 21

Due to sparse pharmacokinetic schedule, CL was not calculated.

Time frame:
Baseline and 1 hour post infusion on Day 1 (Cycles 5, 9, 13, 17, and 21)

No measurements were reported for this outcome.

SecondarySteady State Volume of Distribution (Vss) at Day 1 of Cycles 5, 9, 13, 17, and 21

Due to sparse pharmacokinetic schedule, Vss was not calculated.

Time frame:
Baseline and 1 hour post infusion on Day 1 (Cycles 5, 9, 13, 17, and 21)

No measurements were reported for this outcome.

SecondarySerum Anti-IMC-1121B (Immunogenicity) at Day 1

Data presented are the number of participants with treatment emergent anti-IMC-112B antibodies.

Time frame:
Day 1 (Cycles 1, 5, 9, and 30-day follow-up)
Reported as:
Number · participants
Serum Anti-IMC-1121B (Immunogenicity) at Day 1
participantsIMC-1121B (Ramucirumab) + mFOLFOX-6
Cycle 1 (n=39)0
Cycle 5 (n=33)2
Cycle 9 (n=25)0
30-day Follow-up (n=17)2

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IMC-1121B (Ramucirumab) + mFOLFOX-6—18/48 (37.5%)47/48 (97.9%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventIMC-1121B (Ramucirumab) + mFOLFOX-6
OVARIAN TORSIONReproductive system and breast disorders1/23
DISEASE PROGRESSIONGeneral disorders2/48
PYREXIAGeneral disorders2/48
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders2/48
COAGULOPATHYBlood and lymphatic system disorders1/48
FEBRILE NEUTROPENIABlood and lymphatic system disorders1/48
NEUTROPENIABlood and lymphatic system disorders1/48
ACUTE MYOCARDIAL INFARCTIONCardiac disorders1/48
CARDIO-RESPIRATORY ARRESTCardiac disorders1/48
ABDOMINAL PAINGastrointestinal disorders1/48
Most frequent other events
Showing 10 of 58
Most frequent other events
EventIMC-1121B (Ramucirumab) + mFOLFOX-6
ASTHENIAGeneral disorders35/48
DIARRHOEAGastrointestinal disorders32/48
NEUROTOXICITYNervous system disorders32/48
NEUTROPENIABlood and lymphatic system disorders27/48
HYPERTENSIONVascular disorders27/48
MUCOSAL INFLAMMATIONGeneral disorders26/48
DYSAESTHESIANervous system disorders23/48
NAUSEAGastrointestinal disorders21/48
THROMBOCYTOPENIABlood and lymphatic system disorders17/48
EPISTAXISRespiratory, thoracic and mediastinal disorders15/48

Baseline characteristics

All participants who received any amount of study drug.

Age, Categorical
Age, Categorical(Participants)IMC-1121B (Ramucirumab) + mFOLFOX-6
<=18 years0
Between 18 and 65 years31
>=65 years17
Sex: Female, Male
Sex: Female, Male(Participants)IMC-1121B (Ramucirumab) + mFOLFOX-6
Female23
Male25
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IMC-1121B (Ramucirumab) + mFOLFOX-6
Hispanic or Latino5
Not Hispanic or Latino43
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IMC-1121B (Ramucirumab) + mFOLFOX-6
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White48
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)IMC-1121B (Ramucirumab) + mFOLFOX-6
Canada5
Spain43
08

Study locations

7 sites
  • ImClone Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • ImClone Investigational Site
    Toronto, Ontario M5G-2M9, Canada
  • ImClone Investigational Site
    Montreal, Quebec H2L 4M1, Canada
  • ImClone Investigational Site
    Barcelona, Spain
  • ImClone Investigational Site
    Santander, Spain
  • ImClone Investigational Site
    Seville, Spain
  • ImClone Investigational Site
    Valencia, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Apr 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 3 years 2 months after primary completion. A results delay was requested in Jul 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2009
First posted
Mar 17, 2009
Start
Apr 2009
Primary completionActual
Apr 2011
CompletionActual
Aug 2011
Results delay requested
Jul 26, 2010
Results first posted
Jun 17, 2014
Last update
Jun 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00862784
Responsible party
Sponsor
First posted
Mar 17, 2009
Start date
Apr 2009
Primary completion
Apr 2011
Completion
Aug 2011
Results posted
Jun 17, 2014
Last update
Jun 17, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion